• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 1-A/A filed by Flora Growth Corp.

    8/6/24 5:57:31 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FLGC alert in real time by email
    schemaVersion:
    Form 1-A Issuer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 1-A
    REGULATION A OFFERING STATEMENT
    UNDER THE SECURITIES ACT OF 1933
    OMB APPROVAL


    FORM 1-A

    OMB Number:  3235-0286


    Estimated average burden hours per response: 608.0

    1-A: Filer Information

    Issuer CIK
    0001790169 
    Issuer CCC
    XXXXXXXX 
    DOS File Number
     
    Offering File Number
    024-12465 
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
    Would you like a Return Copy? Checkbox not checked
    Notify via Filing Website only? Checkbox not checked
    Since Last Filing? Checkbox not checked

    Submission Contact Information

    Name
     
    Phone
     
    E-Mail Address
     

    1-A: Item 1. Issuer Information

    Issuer Infomation

    Exact name of issuer as specified in the issuer's charter

    Flora Growth Corp. 

    Jurisdiction of Incorporation / Organization

    ONTARIO, CANADA  

    Year of Incorporation

    2019 

    CIK

    0001790169 

    Primary Standard Industrial Classification Code

    MEDICINAL CHEMICALS & BOTANICAL PRODUCTS 

    I.R.S. Employer Identification Number

    00-0000000 

    Total number of full-time employees

    102 

    Total number of part-time employees

    11 

    Contact Infomation

    Address of Principal Executive Offices

    Address 1

    3230 W. COMMERCIAL BOULEVARD, SUITE 180 

    Address 2

     

    City

    FORT LAUDERDALE 

    State/Country

    FLORIDA  

    Mailing Zip/ Postal Code

    33309 

    Phone

    954-842-4989 

    Provide the following information for the person the Securities and Exchange Commission's staff should call in connection with any pre-qualification review of the offering statement.

    Name

    Richard Raymer 

    Address 1

     

    Address 2

     

    City

     

    State/Country

     

    Mailing Zip/ Postal Code

     

    Phone

     

    Provide up to two e-mail addresses to which the Securities and Exchange Commission's staff may send any comment letters relating to the offering statement. After qualification of the offering statement, such e-mail addresses are not required to remain active.

    Financial Statements

    Use the financial statements for the most recent period contained in this offering statement to provide the following information about the issuer. The following table does not include all of the line items from the financial statements. Long Term Debt would include notes payable, bonds, mortgages, and similar obligations. To determine "Total Revenues" for all companies selecting "Other" for their industry group, refer to Article 5-03(b)(1) of Regulation S-X. For companies selecting "Insurance", refer to Article 7-04 of Regulation S-X for calculation of "Total Revenues" and paragraphs 5 and 7 of Article 7-04 for "Costs and Expenses Applicable to Revenues".

    Industry Group (select one) Radio button not checked Banking Radio button not checked Insurance Radio button checked Other

    Balance Sheet Information

    Cash and Cash Equivalents

    $ 4156000.00 

    Investment Securities
    $ 0.00 
    Total Investments

    $  

    Accounts and Notes Receivable

    $ 3218000.00 

    Loans

    $  

    Property, Plant and Equipment (PP&E):

    $ 786000.00 

    Property and Equipment

    $  

    Total Assets

    $ 24274000.00 

    Accounts Payable and Accrued Liabilities

    $ 5005000.00 

    Policy Liabilities and Accruals

    $  

    Deposits

    $  

    Long Term Debt

    $ 1817000.00 

    Total Liabilities

    $ 21136000.00 

    Total Stockholders' Equity

    $ 3138000.00 

    Total Liabilities and Equity

    $ 24274000.00 

    Statement of Comprehensive Income Information

    Total Revenues

    $ 18031000.00 

    Total Interest Income

    $  

    Costs and Expenses Applicable to Revenues

    $ 14177000.00 

    Total Interest Expenses

    $  

    Depreciation and Amortization

    $ 74000.00 

    Net Income

    $ -3374000.00 

    Earnings Per Share - Basic

    $ -0.38 

    Earnings Per Share - Diluted

    $ -0.38 

    Name of Auditor (if any)

    N/A 

    Outstanding Securities

    Common Equity

    Name of Class (if any) Common Equity

    Common Shares 

    Common Equity Units Outstanding

    13366535 

    Common Equity CUSIP (if any):

    339764201 

    Common Equity Units Name of Trading Center or Quotation Medium (if any)

    Nasdaq Capital Market 

    Preferred Equity

    Preferred Equity Name of Class (if any)

     

    Preferred Equity Units Outstanding

    0 

    Preferred Equity CUSIP (if any)

     

    Preferred Equity Name of Trading Center or Quotation Medium (if any)

     

    Debt Securities

    Debt Securities Name of Class (if any)

     

    Debt Securities Units Outstanding

    0 

    Debt Securities CUSIP (if any):

     

    Debt Securities Name of Trading Center or Quotation Medium (if any)

     

    1-A: Item 2. Issuer Eligibility

    Issuer Eligibility

    Check this box to certify that all of the following statements are true for the issuer(s)

    Checkbox checked

    • Organized under the laws of the United States or Canada, or any State, Province, Territory or possession thereof, or the District of Columbia.
    • Principal place of business is in the United States or Canada.
    • Not subject to section 13 or 15(d) of the Securities Exchange Act of 1934.
    • Not a development stage company that either (a) has no specific business plan or purpose, or (b) has indicated that its business plan is to merge with an unidentified company or companies.
    • Not an investment company registered or required to be registered under the Investment Company Act of 1940.
    • Not issuing fractional undivided interests in oil or gas rights, or a similar interest in other mineral rights.
    • Not issuing asset-backed securities as defined in Item 1101 (c) of Regulation AB.
    • Not, and has not been, subject to any order of the Commission entered pursuant to Section 12(j) of the Exchange Act (15 U.S.C. 78l(j)) within five years before the filing of this offering statement.
    • Has filed with the Commission all the reports it was required to file, if any, pursuant to Rule 257 during the two years immediately before the filing of the offering statement (or for such shorter period that the issuer was required to file such reports).

    1-A: Item 3. Application of Rule 262

    Application Rule 262

    Check this box to certify that, as of the time of this filing, each person described in Rule 262 of Regulation A is either not disqualified under that rule or is disqualified but has received a waiver of such disqualification.

    Checkbox checked

    Check this box if "bad actor" disclosure under Rule 262(d) is provided in Part II of the offering statement.

    Checkbox not checked

    1-A: Item 4. Summary Information Regarding the Offering and Other Current or Proposed Offerings

    Summary Infomation

    Check the appropriate box to indicate whether you are conducting a Tier 1 or Tier 2 offering Radio button not checked Tier1 Radio button checked Tier2
    Check the appropriate box to indicate whether the financial statements have been audited Radio button not checked Unaudited Radio button checked Audited
    Types of Securities Offered in this Offering Statement (select all that apply)
    Checkbox checkedEquity (common or preferred stock) 
    Does the issuer intend to offer the securities on a delayed or continuous basis pursuant to Rule 251(d)(3)? Radio button checked Yes Radio button not checked No
    Does the issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
    Does the issuer intend to price this offering after qualification pursuant to Rule 253(b)? Radio button not checked Yes Radio button checked No
    Will the issuer be conducting a best efforts offering? Radio button checked Yes Radio button not checked No
    Has the issuer used solicitation of interest communications in connection with the proposed offering? Radio button not checked Yes Radio button checked No
    Does the proposed offering involve the resale of securities by affiliates of the issuer? Radio button not checked Yes Radio button checked No
    Number of securities offered
    30000000 
    Number of securities of that class outstanding
    13366535 

    The information called for by this item below may be omitted if undetermined at the time of filing or submission, except that if a price range has been included in the offering statement, the midpoint of that range must be used to respond. Please refer to Rule 251(a) for the definition of "aggregate offering price" or "aggregate sales" as used in this item. Please leave the field blank if undetermined at this time and include a zero if a particular item is not applicable to the offering.

    Price per security
    $ 2.5000 
    The portion of the aggregate offering price attributable to securities being offered on behalf of the issuer
    $ 75000000.00 
    The portion of the aggregate offering price attributable to securities being offered on behalf of selling securityholders
    $ 0.00 
    The portion of the aggregate offering price attributable to all the securities of the issuer sold pursuant to a qualified offering statement within the 12 months before the qualification of this offering statement
    $ 0.00 
    The estimated portion of aggregate sales attributable to securities that may be sold pursuant to any other qualified offering statement concurrently with securities being sold under this offering statement
    $ 0.00 
    Total (the sum of the aggregate offering price and aggregate sales in the four preceding paragraphs)
    $ 75000000.00 

    Anticipated fees in connection with this offering and names of service providers

    Underwriters - Name of Service Provider
    N/A
    Underwriters - Fees
    $ 0.00 
    Sales Commissions - Name of Service Provider
    Aegis Capital Corp.
    Sales Commissions - Fee
    $ 5250000.00 
    Finders' Fees - Name of Service Provider
    N/A
    Finders' Fees - Fees
    $ 0.00 
    Accounting or Audit - Name of Service Provider
    Davidson & Company LLP
    Accounting or Audit - Fees
    $ 40000.00 
    Legal - Name of Service Provider
    Dorsey & Whitney LLP; Kaufman & Canoles LLP
    Legal - Fees
    $ 250000.00 
    Promoters - Name of Service Provider
    N/A
    Promoters - Fees
    $ 0.00 
    Blue Sky Compliance - Name of Service Provider
    Kaufman & Canoles LLP
    Blue Sky Compliance - Fees
    $ 10000.00 
    CRD Number of any broker or dealer listed:
    000015007 
    Estimated net proceeds to the issuer
    $ 69450000.00 
    Clarification of responses (if necessary)
     

    1-A: Item 5. Jurisdictions in Which Securities are to be Offered

    Jurisdictions in Which Securities are to be Offered

    Using the list below, select the jurisdictions in which the issuer intends to offer the securities

    Selected States and Jurisdictions

    NEW YORK
    CANADA (FEDERAL LEVEL)

    Using the list below, select the jurisdictions in which the securities are to be offered by underwriters, dealers or sales persons or check the appropriate box

    None Checkbox not checked
    Same as the jurisdictions in which the issuer intends to offer the securities Checkbox checked
    Selected States and Jurisdictions

    NEW YORK
    CANADA (FEDERAL LEVEL)

    1-A: Item 6. Unregistered Securities Issued or Sold Within One Year

    Unregistered Securities Issued or Sold Within One Year

    None Checkbox not checked

    Unregistered Securities Issued

    As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

    (a)Name of such issuer
    Flora Growth Corp. (the Corporation) 
    (b)(1) Title of securities issued
    On September 21, 2023, the Corporation issued: (i) warrants to certain institutional investors to purchase up to 1,369,000 common shares of the Corporation, and (ii) warrants to A.G.P. to purchase up to 54,760 common shares of the Corporation.
     
    (2) Total Amount of such securities issued
    1423760
    (3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
    0 
    (c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
    The Corporation received net proceeds of $2.4 million pursuant to the private placements on September 21, 2023
     
    (2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
     

    Unregistered Securities Issued

    As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

    (a)Name of such issuer
    Flora Growth Corp. (the Corporation) 
    (b)(1) Title of securities issued
    On April 22, 2024, the Corporation issued 2,135,199 common shares to TruHC Holding GmbH (TrueHC), pursuant to the Stock Purchase Agreement by and between the Corporation and TruHC dated April 16, 2024 (the Stock Purchase Agreement).
     
    (2) Total Amount of such securities issued
    2135199
    (3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
    0 
    (c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
    The Corporation received 19,266 shares of Common Stock of TrueHC pursuant to the Stock Purchase Agreement.
     
    (2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
     

    Unregistered Securities Issued

    As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

    (a)Name of such issuer
    Flora Growth Corp. (the Corporation) 
    (b)(1) Title of securities issued
    On June 4, 2024, the Corporation issued 550,000 common shares of the Corporation to Lifeist Wellness Inc. (Lifeist), pursuant to the Share Purchase Agreement by and between the Corporation and Lifeist dated June 4, 2024 (the Share Purchase Agreement).
     
    (2) Total Amount of such securities issued
    550000
    (3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
    0 
    (c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
    The Corporation received all of the issued and outstanding common shares of Australian Vaporizers Pty Ltd., pursuant to the Share Purchase Agreement.
     
    (2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
     

    Unregistered Securities Act

    (d) Indicate the section of the Securities Act or Commission rule or regulation relied upon for exemption from the registration requirements of such Act and state briefly the facts relied upon for such exemption
    N/A
     
    Get the next $FLGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLGC

    DatePrice TargetRatingAnalyst
    11/25/2024$4.00Buy
    Aegis Capital
    10/13/2021$10.00Buy
    Roth Capital
    6/23/2021$6.00Buy
    MKM Partners
    More analyst ratings

    $FLGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Flora Growth Corp. Announces Name Change to ZeroStack Corp., Furthering Its Strategy as an AI-Focused Asset Management Company

    Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Flora Growth Corp. (NASDAQ:FLGC) (the "Company") today announced that it will change its corporate name to "ZeroStack Corp." The name change is expected to become effective on or around January 29, 2026, on the Nasdaq Capital Market (the "Nasdaq"). Concurrent with the corporate name change, the Company's common shares (the "Common Shares") will trade on the Nasdaq under the symbol "ZSTK".The name and ticker change reflect the Company's evolution toward an AI-focused, asset management strategy with its first investment in $0G, the native asset of the 0G decentralized AI operating system ("0G Token").ZeroStack is focused on providing expo

    1/27/26 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SRx Health Solutions Appoints Sammy Dorf to Board of Directors

    TAMPA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE:SRXH) (the "Company") today announced the appointment of Sammy Dorf, Esq. to its Board of Directors. Sammy is a pioneering force in the modern cannabis economy and one of the industry's most accomplished dealmakers, strategists, and growth architects. Most recently serving as Executive Chairman of Flora Growth Corp. (NASDAQ:FLGC), Sammy guided the company through a transformative phase marked by innovation, disciplined expansion, and a strategic transition into a crypto treasury company. With nearly a decade of leadership at the intersection of cannabis, capital markets, and strategic development, Sammy b

    11/10/25 8:00:00 AM ET
    $FLGC
    $SRXH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Flora Growth Corp. Announces Second Purchase of 0G, the Fuel of the 0G Decentralized AI Network

    Fort Lauderdale, Florida--(Newsfile Corp. - October 21, 2025) - Flora Growth Corp. (NASDAQ:FLGC) (the "Company"), which is set to rebrand as ZeroStack, and is the first public company to offer exposure to Decentralized AI through the accumulation of $0G, the native cryptocurrency of the distributed AI infrastructure project 0G ("0G"), today announced the purchase of 880,025 $0G at an average price of $2.27. The purchase represents the Company's second acquisition of $0G since its most recent $401 million fundraising and strategic shift to build the world's first publicly listed 0G treasury.Below is a summary of the Company's current $0G position and key per-share metrics as of October 21, 20

    10/21/25 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital initiated coverage on Flora Growth with a new price target

    Aegis Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $4.00

    11/25/24 8:07:10 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Flora Growth with a new price target

    Roth Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $10.00

    10/13/21 9:00:51 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MKM Partners initiated coverage on Flora Growth with a new price target

    MKM Partners initiated coverage of Flora Growth with a rating of Buy and set a new price target of $6.00

    6/23/21 5:36:01 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    SEC Filings

    View All

    Flora Growth Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ZeroStack Corp. (0001790169) (Filer)

    1/29/26 5:20:48 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Flora Growth Corp.

    424B5 - Flora Growth Corp. (0001790169) (Filer)

    1/27/26 5:25:46 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Flora Growth Corp.

    FWP - Flora Growth Corp. (0001790169) (Subject)

    1/27/26 4:05:35 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Starke Clifford bought $6,455 worth of shares (6,795 units at $0.95), increasing direct ownership by 13,324% to 6,846 units (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/17/24 10:17:39 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wolkin Harold bought $24,255 worth of shares (25,000 units at $0.97) (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/11/24 5:43:51 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Starke Clifford bought $48 worth of shares (51 units at $0.95), increasing direct ownership by 0.01% to 474,046 units (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/6/24 5:25:10 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Zeifman Laurence

    3 - Flora Growth Corp. (0001790169) (Issuer)

    1/15/26 11:54:20 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CFO Vaiman Dany

    4 - Flora Growth Corp. (0001790169) (Issuer)

    12/22/25 5:15:05 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO Reis-Faria Daniel

    4 - Flora Growth Corp. (0001790169) (Issuer)

    12/22/25 5:13:21 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Leadership Updates

    Live Leadership Updates

    View All

    SRx Health Solutions Appoints Sammy Dorf to Board of Directors

    TAMPA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE:SRXH) (the "Company") today announced the appointment of Sammy Dorf, Esq. to its Board of Directors. Sammy is a pioneering force in the modern cannabis economy and one of the industry's most accomplished dealmakers, strategists, and growth architects. Most recently serving as Executive Chairman of Flora Growth Corp. (NASDAQ:FLGC), Sammy guided the company through a transformative phase marked by innovation, disciplined expansion, and a strategic transition into a crypto treasury company. With nearly a decade of leadership at the intersection of cannabis, capital markets, and strategic development, Sammy b

    11/10/25 8:00:00 AM ET
    $FLGC
    $SRXH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Flora Growth Corp. Appoints BitGo as Custodian for $0G Treasury

    Fort Lauderdale, Florida--(Newsfile Corp. - October 16, 2025) - Flora Growth Corp. (NASDAQ:FLGC), which is set to rebrand as ZeroStack (the "Company"), the first and largest decentralized AI treasury company, has appointed BitGo Trust Company, Inc. ("BitGo") to provide institutional-grade custody for the Company's $0G treasury.BitGo, the digital asset infrastructure company, has enabled its clients to securely navigate the digital asset space since 2013 by delivering custody, wallets, staking, trading, financing, and settlement services from regulated cold storage. The appointment of BitGo is proof of the Company's focused approach to transparency, security, regulatory compliance and operati

    10/16/25 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. Appoints Clifford Starke as Chief Executive Officer and Dany Vaiman as Chief Financial Officer; Regains Compliance with NASDAQ Minimum Bid Requirement

    Fort Lauderdale, Florida--(Newsfile Corp. - June 27, 2023) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a consumer-packaged goods leader serving all 50 states with 15,000+ points of distribution around the world and a pharmaceutical distributor in 28 countries, announced today that Clifford Starke has been appointed as Chief Executive Officer to lead its global operations and Dany Vaiman has been appointed as Chief Financial Officer. Mr. Starke, who previously served as President of the Company, takes over for Hussein Rakine, who resigned as CEO but will remain on the Company's Board of Directors. Mr. Rakine expressed his confidence in the appointment, stating, "Clifford's

    6/27/23 4:05:00 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:01:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Flora Growth Corp.

    SC 13G/A - Flora Growth Corp. (0001790169) (Subject)

    11/14/24 2:24:54 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Financials

    Live finance-specific insights

    View All

    Flora Growth Sets Third Quarter 2022 Conference Call for November 28, 2022, at 4:30 P.M. ET

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, will host its third quarter 2022 earnings call via webcast on Monday, November 28 at 4:30 p.m. ET. During the webcast, Flora management will deliver financial and operational results for the third quarter ended September 30, 2022, and provide updates on Flora's commercial wholesale operations, house of brands and life sciences division strategies. Following the webcast, Flora management will open the call to analysts, media and investors in a Q&A format. Live Webcast Details Date: Monday, November 28, 2022 Time: 4:30 p.m. ET

    11/21/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth to Host Webcast Discussing M&A Activity and International Market Opportunities - Wednesday, October 26, 2022

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that the Company will be hosting an analyst call on Wednesday, October 26, 2022, at 02:00 p.m. EST via webcast to discuss Flora Growth's recent M&A activity and strategic growth opportunities. The conference call and live webcast will invite analysts to pose questions to Flora and Franchise Global Health's leadership teams regarding the recent announcement of the definitive agreement of acquisition between the two companies and the opportunities within the cannabis industry on the global stage. To access this ca

    10/25/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Awarded Best M&A Deal at Benzinga Cannabis Capital Conference

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that the Company received the Best M&A Deal award at Benzinga's 2022 Cannabis Capital Conference in Chicago. "We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives including acquiring products, expertise, expanding distribution, and customers," said Luis Merchan, Chairman and CEO of Flora. Flora completed the acquisition of JustCBD in February 2022, and it immediately offered the Company an established CPG brand with a por

    9/13/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care